Restricted accessResearch articleFirst published online 2025
Alterations in erythrocyte deformability,aggregation,and blood viscosity in rheumatoid arthritis and systemic lupus erythematosus patients: A comparative haemorheological analysis
This study investigated haemorheological alterations in patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE).
Methods
A total of 136 individuals were enrolled, comprising 52 healthy controls, 51 RA patients, and 33 SLE patients. Blood samples were collected at the University of Health Sciences Sultan Abdulhamid Han Training and Research Hospital in Istanbul, Türkiye. Whole blood and plasma viscosity, along with red blood cell (RBC) deformability and aggregation, were analysed using a Brookfield viscometer and a laser-assisted optical rotational cell analyser (LORRCA).
Results
RBC deformability was reduced in both patient groups compared to controls (EImax: RA 0.645, SLE 0.642, control 0.648), while RBC aggregation was markedly increased (AI: RA 75.66, SLE 74.73, control 65.5) (p < 0.05). Plasma and whole blood viscosity were also elevated in RA and SLE groups, with the highest values observed in SLE patients (PV: RA 1.43, SLE 1.48, control 1.31).
Conclusions
RA and SLE patients show notable impairments in haemorheological parameters. Evaluating RBC deformability, aggregation, and plasma viscosity may help clarify disease mechanisms and guide therapeutic strategies to mitigate vascular complications and tissue damage in autoimmune disorders.
RaduAFBungauSG. Management of rheumatoid arthritis: an overview. Cells2021; 10: 2857.
3.
KurowskaWKuca-WarnawinEHRadzikowskaA, et al.The role of anti-citrullinated protein antibodies (ACPA) in the pathogenesis of rheumatoid arthritis. Cent Eur J Immunol2017; 42: 390–398.
4.
WegnerNLundbergKKinlochA, et al.Autoimmunity to specific citrullinated proteins gives the first clues to the etiology of rheumatoid arthritis. Immunol Rev2010; 233: 34–54.
5.
SilmanAJPearsonJE. Epidemiology and genetics of rheumatoid arthritis. Arthritis Res2002; 4: S265–S272.
6.
MyasoedovaEDavisJMattesonEL, et al.Is the epidemiology of rheumatoid arthritis changing? Results from a population-based incidence study, 1985–2014. Ann Rheum Dis2020; 79: 440–444.
7.
Van Der Helm-Van MilAHMVerpoortKNBreedveldFC, et al.The HLA-DRB1 shared epitope alleles are primarily a risk factor for anti-cyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritis. Arthritis Rheum2006; 54: 1117–1121.
8.
DingBPadyukovLLundströmE, et al.Different patterns of associations with anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative rheumatoid arthritis in the extended major histocompatibility complex region. Arthritis Rheum2009; 60: 30–38.
9.
FiresteinGSMcInnesIB. Immunopathogenesis of rheumatoid arthritis. Immunity2017; 46: 183–196.
10.
KiriakidouMChingCL. Systemic lupus erythematosus. Ann Intern Med2020; 172: ITC81–ITC96.
11.
TsokosGC. Systemic lupus erythematosus. N Engl J Med2011; 365: 2110–2121.
12.
YuHCLuMC. The roles of anti-citrullinated protein antibodies in the immunopathogenesis of rheumatoid arthritis. Ci Ji Yi Xue Za Zhi2019; 31: 5–10.
13.
PetriMOrbaiAMAlarcõnGS, et al.Derivation and validation of the systemic lupus ınternational collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum2012; 64: 2677–2686.
14.
LarosaMIaccarinoLGattoM, et al.Advances in the diagnosis and classification of systemic lupus erythematosus. Expert Rev Clin Immunol2016; 12: 1309–1320.
15.
YuHNagafuchiYFujioK. Clinical and ımmunological biomarkers for systemic lupus erythematosus. Biomolecules2021; 11: 928.
16.
ShinSKuYParkMS, et al.Deformability of red blood cells: a determinant of blood viscosity. J Mech Sci Technol2005; 19: 216–223.
17.
LoweGDOLeeAJRumleyA, et al.Blood viscosity and risk of cardiovascular events: the Edinburgh artery study. Br J Haematol1997; 96: 168–173.
18.
GalanzhaEIZharovVP. In vivo photoacoustic and photothermal cytometry for monitoring multiple blood rheology parameters. Cytometry A2011; 79A: 746–757.
19.
BaskurtOKMeiselmanHJ. Blood rheology and hemodynamics. Semin Thromb Hemost2003; 29: 435–450.
20.
Vent-SchmidtJWaltzXRomanaM, et al.Blood thixotropy in patients with sickle cell anaemia: role of haematocrit and red blood cell rheological properties. PLoS One2014; 9: e114412.
21.
ChienS. Red cell deformability and its relevance to blood flow. Annu Rev Physiol1987; 49: 177–192.
ConnesPAlexyTDetterichJ, et al.The role of blood rheology in sickle cell disease. Blood Rev2016; 30: 111–118.
24.
DixeyJSolymossyCYoungA. Is it possible to predict radiological damage in early rheumatoid arthritis (RA)? A report on the occurrence, progression, and prognostic factors of radiological erosions over the first 3 years in 866 patients from the early RA study (ERAS). J Rheumatol Suppl2004; 69: 48–54.
25.
GudmundssonMBjelleA. Vıscosıty of plasma and blood ın rheumatoıd arthrıtıs. Rheumatology1993; 32: 774–779.
26.
Llaudet-PlanasEVives-CorronsJLRizzutoV, et al.Osmotic gradient ektacytometry: a valuable screening test for hereditary spherocytosis and other red blood cell membrane disorders. Int J Lab Hematol2018; 40: 94–102.
27.
Da CostaLGalimandJFenneteauO, et al.Hereditary spherocytosis, elliptocytosis, and other red cell membrane disorders. Blood Rev2013; 27: 167–178.
28.
Da CostaLSunerLGalimandJ, et al.Diagnostic tool for red blood cell membrane disorders: assessment of a new generation ektacytometer. Blood Cells Mol Dis2016; 56: 9–22.
29.
LazarovaEGulbisBVan OirschotB, et al.Next-generation osmotic gradient ektacytometry for the diagnosis of hereditary spherocytosis: interlaboratory method validation and experience. Clin Chem Lab Med2017; 55: 394–402.
30.
UygurLKabasakal IlterMHelvaciN, et al.Investigating the blood rheology in the first trimester pregnancies with high risk for preeclampsia. Clin Hemorheol Microcirc2024; 86: 519–530.
31.
Olumuyiwa-AkeredoluOOOPretoriusE. Platelet and red blood cell interactions and their role in rheumatoid arthritis. Rheumatol Int2015; 35: 1955–1964.
32.
De HuZChenYZhangL, et al.Red blood cell distribution width is a potential index to assess the disease activity of systemic lupus erythematosus. Clin Chim Acta2013; 425: 202–205.
33.
LuquitaAUrliLSvetazMJ, et al.Erythrocyte aggregation in rheumatoid arthritis: cell and plasma factor’s role. Clin Hemorheol Microcirc2009; 41: 49–56.
34.
GasparyanAYStavropoulos-KalinoglouAMikhailidisDP, et al.Platelet function in rheumatoid arthritis: arthritic and cardiovascular implications. Rheumatol Int2011; 31: 153–164.
35.
ErmuratSTezcanD. Sistemik lupus eritematozus hastalarında inflamasyon belirteci ve yüksek hastalık aktivite göstergesi olarak yeni hematolojik indeksler [New hematological ındices as markers of ınflammation and ındicators of high disease activity in patients with systemic lupus erythematosus]. Uludağ Üniversitesi Tıp Fakültesi Dergisi2022; 48: 189–196.
36.
YılmazB. Comparison of neutrophil/lymphocyte, platelet/lymphocyte ratio and mpv values in patients using methotrexate and anti-TNF in rheumatoid arthritis. J Anatolian Med Res2018; 3: 23–28.
37.
SmolenJSAletahaDBartonA, et al.Rheumatoid arthritis. Nat Rev Dis Primers2018; 4: 18001.
Olumuyiwa-AkeredoluOSomaPBuysAV, et al.Characterizing pathology in erythrocytes using morphological and biophysical membrane properties: relation to impaired hemorheology and cardiovascular function in rheumatoid arthritis. Biochim Biophys Acta Biomembr2017; 1859: 2381–2391.
41.
LuquitaAUrliLDominighiniA, et al.Haemorheological variables as a rheumatoid arthritis activity indicator. Clin Hemorheol Microcirc2004; 30: 9–16.
42.
SantosMJPedroLMCanhãoH, , et al.Hemorheological parameters are related to subclinical atherosclerosis in systemic lupus erythematosus and rheumatoid arthritis patients. Atherosclerosis2011; 219: 821–826.
43.
SpenglerMISvetazMJLerouxMB, et al.Erythrocyte aggregation in patients with systemic lupus erythematosus. Clin Hemorheol Microcirc2011; 47: 279–285.
44.
ErnstEHeinAMeurerM, et al.Blood rheology in lupus erythematosus. Ann Rheum Dis1991; 50: 710–712.
45.
BoothSChohanSCurranJC, et al.Whole blood viscosity and arterial thrombotic events in patients with systemic lupus erythematosus. Arthritis Rheum2007; 57: 845–850.
46.
YapHYTeeSZWongMM, et al.Pathogenic role of immune cells in rheumatoid arthritis: implications in clinical treatment and biomarker development. Cells2018; 7: 161.
47.
LiWLiHSongW, et al.Differential diagnosis of systemic lupus erythematosus and rheumatoid arthritis with complements C3 and C4 and C-reactive protein. Exp Ther Med2013; 6: 1271–1276.
48.
PopeJEChoyEH. C-reactive protein and implications in rheumatoid arthritis and associated comorbidities. Semin Arthritis Rheum2021; 51: 219–229.
AlghamdiM. Red blood cell distribution width: a potential inexpensive marker for disease activity in patients with rheumatic diseases: scoping review. Open Access Rheumatol2023; 15: 173–180.
51.
AhlersMJLoweryBDFarber-EgerE, et al.Heart failure risk associated with rheumatoid arthritis-related chronic inflammation. J Am Heart Assoc2020; 9: e014661.
52.
GhiranICZeidelMLShevkoplyasSS, et al.Systemic lupus erythematosus serum deposits C4d on red blood cells, decreases red blood cell membrane deformability, and promotes nitric oxide production. Arthritis Rheum2011; 63: 503–512.
53.
ZinelluAMangoniAA. Platelet and red blood cell volume ındices in patients with rheumatoid arthritis: a systematic review and meta-analysis. Diagnostics2022; 12(11): 2633.
